# Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes

> **NCT03758144** · NA · UNKNOWN · sponsor: **Zagazig University** · enrollment: 80 (estimated)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** Rifaximin 200 MG

## Key facts

- **NCT ID:** NCT03758144
- **Lead sponsor:** Zagazig University
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-01
- **Primary completion:** 2019-06
- **Final completion:** 2019-07-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758144, "Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03758144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*